Vaccinogen, a specialist in cancer immunotherapy development, has appointed Peter Morsing, a 20-year pharmaceutical industry veteran, as Head of Business Development.
The company is in the final stages of the development of OncoVAX, a treatment designed to prevent the recurrence of colon cancer and potentially other solid tumours that uses a patient's own tumour cells to induce an immune response against remaining cancer cells and prevent disease recurrence.
Previously, Morsing held roles of increasing responsibility with AstraZeneca, where he was most recently Search and Evaluation Director and responsible for identification and evaluation of novel therapeutic approaches to cardiovascular and metabolic diseases.
While with AstraZeneca, he was also Licensing Director, Strategic Partnering and Business Development, leading global teams in the evaluation of external therapeutic licensing opportunities specialising in diabetes and obesity.
Prior to these positions, Morsing also served as Portfolio Manager for the Second Swedish National Pension Fund where he was responsible for evaluating and managing investments in the pharmaceutical and biotechnology sectors.
